MARKET

AVLN

AVLN

AVALYN PHARMACEUTICALS INC
NASDAQ
29.73
+1.01
+3.52%
After Hours: 29.73 0 0.00% 19:34 07/23 EDT
OPEN
28.37
PREV CLOSE
28.72
HIGH
29.92
LOW
28.37
VOLUME
281.81K
TURNOVER
--
52 WEEK HIGH
33.32
52 WEEK LOW
24.15
MARKET CAP
1.32B
P/E (TTM)
-1.3617
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVLN last week (0713-0717)?
Weekly Report · 3d ago
Weekly Report: what happened at AVLN last week (0706-0710)?
Weekly Report · 07/13 10:37
Weekly Report: what happened at AVLN last week (0629-0703)?
Weekly Report · 07/06 10:42
Weekly Report: what happened at AVLN last week (0622-0626)?
Weekly Report · 06/29 10:36
Weekly Report: what happened at AVLN last week (0615-0619)?
Weekly Report · 06/22 10:48
Avalyn Pharma completes target enrollment in MIST trial
TipRanks · 06/17 12:15
Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis
PUBT · 06/17 12:02
AVALYN COMPLETES TARGET ENROLLMENT IN PHASE 2B MIST TRIAL OF AP01 (INHALED PIRFENIDONE) FOR PATIENTS WITH PROGRESSIVE PULMONARY FIBROSIS
Reuters · 06/17 12:00
More
About AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Webull offers Avalyn Pharma stock information, including NASDAQ: AVLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVLN stock methods without spending real money on the virtual paper trading platform.